# EDGAR Filing Document

**Accession Number:** 0002007191
**File Stem:** 0002007191-25-000071
**Filing Date:** 2025-10
**Character Count:** 2645
**Document Hash:** f4e91216535211e156febb76301a9017
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002007191-25-000071.hdr.sgml**: 20251014

**ACCESSION NUMBER**: 0002007191-25-000071

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20251014

**FILED AS OF DATE**: 20251014

**DATE AS OF CHANGE**: 20251014

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Telix Pharmaceuticals Ltd
- **CENTRAL INDEX KEY:** 0002007191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42128
- **FILM NUMBER:** 251389913

**BUSINESS ADDRESS:**
- **STREET 1:** 55 FLEMINGTON ROAD
- **CITY:** NORTH MELBOURNE
- **STATE:** C3
- **ZIP:** 3051
- **BUSINESS PHONE:** 61 3 9093 3855

**MAIL ADDRESS:**
- **STREET 1:** 55 FLEMINGTON ROAD
- **CITY:** NORTH MELBOURNE
- **STATE:** C3
- **ZIP:** 3051

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2025

Commission File Number: **001-42128**

**Telix Pharmaceuticals Limited**

(Translation of registrant's name into English)

**55 Flemington Road**

**North Melbourne, Victoria 3051, Australia**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On October 14, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled "Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded," which is attached to this Form 6-K as Exhibit 99.1.

<u>[99.1](prq3.htm)</u> Press release – October 14, 2025

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Telix Pharmaceuticals Limited**  | **Telix Pharmaceuticals Limited**  |
| Date: October 14, 2025  | By:  | /s/ Genevieve Ryan  |
|  |  | Name: Genevieve Ryan  |
|  |  | Title: Company Secretary  |

---

------

## Exhibit 99.1

![prq3.pdf page 1](prq31.jpg)

![prq3.pdf page 2](prq32.jpg)

![prq3.pdf page 3](prq33.jpg)

![prq3.pdf page 4](prq34.jpg)

![prq3.pdf page 5](prq35.jpg)